Balance Sheet
Cash Flow Statement
Cash from Financing ActivitiesCash from Financing ActivitiesCash from OperationsCash from OperationsChange in Account PayablesChange in Account PayablesChange in Accured ExpensesChange in Accured ExpensesChange in CashDepreciation & Amortization (CF)Depreciation & Amortization (CF)Free Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet Cash FlowNet IncomeNon-cash ItemsNon-cash ItemsShare-based CompensationShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Spruce Biosciences (SPRB) Cash from Investing Activities (2022 - 2023)

Spruce Biosciences (SPRB) has disclosed Cash from Investing Activities for 2 consecutive years, with $9.3 million as the latest value for Q4 2023.

  • Quarterly Cash from Investing Activities fell 36.17% to $9.3 million in Q4 2023 from the year-ago period, while the trailing twelve-month figure was $9.3 million through Sep 2024, down 84.77% year-over-year, with the annual reading at $55.8 million for FY2023, 135.43% up from the prior year.
  • Cash from Investing Activities for Q4 2023 was $9.3 million at Spruce Biosciences, down from $14.0 million in the prior quarter.
  • The five-year high for Cash from Investing Activities was $33.5 million in Q2 2022, with the low at -$16.9 million in Q3 2022.